CHOLINE-2: Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
Study Details
Study Description
Brief Summary
Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency. French health authorities currently preconize a non-rug approach based on cognitive remediation or stimulation.
The aim of this study is to compare the efficiency of the 2 approaches (non-drug versus donepezil) on the symptoms of Alzheimer's disease after 6 months of treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 3 |
Detailed Description
Randomized multicentric open-label study, comparison of 2 therapeutic strategies.
2 arms:
-
Standard of care, non-drug approach: following the recommendations of the Alzheimer's disease care by the Frenchh Health Authority. The care is cognitive, psychic, functional or social and centered on the patient and his environment. This care is best carried out by the memory consultations participating in this study and having extensive experience in the care of Alzheimer patients. It is usually based in particular on the prescription of cognitive stimulation sessions by a speech therapist and a mobile Alzheimer specialist team at home for cognitive remediation sessions.
-
Donepezil group: Management similar to the previous arm plus addition of Donepezil 5 mg per os once a day for one month and then 10 mg per os once a day until the 6th month.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Cognitive remediation Non-drug treatment, cognitive remediation, cognitive stimulation |
|
| Experimental: Cognitive remediation + Donepezil Non-drug treatment, cognitive remediation, cognitive stimulation + Donepezil |
Drug: Donepezil
Donepezil 5 mg per day during one month, then 10 mg per day during 5 months.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Difference of change in the MMSE score [26 weeks]
Difference of change in the MMSE score between baseline and 26 weeks in the 2 ams (donepezil versus non-drug). MMSE is measured at baseline, 6 weeks, 13 weeks, and 26 weeks.
Secondary Outcome Measures
- Difference of change in the ADAS-Cog scale [26 weeks]
Difference of change in the ADAS-Cog scale between baseline and 26 weeks in the 2 ams (donepezil versus non-drug). ADAS-Cog scale = Alzheimer's Disease Assessment Scale-Cognitive Subscale, scored from 0 to 70
- Difference of change in the CDR scale [26 weeks]
Difference of change in the CDR scale between baseline and 26 weeks in the 2 ams (donepezil versus non-drug). CDR scale = Clinical Dementia Rating, scored from 0 to 3
- Difference of change in the ADL scale [26 weeks]
Difference of change in the ADL scale between baseline and 26 weeks in the 2 ams (donepezil versus non-drug). ADL scale = Autonomy scale on daily activities, scored from 0 to 78
- Difference of change in the quality of life scale [26 weeks]
Difference of change in the quality of life scale between baseline and 26 weeks in the 2 ams (donepezil versus non-drug).
- Difference of change in the ZARIT scale [26 weeks]
Difference of change in the ZARIT scale between baseline and 26 weeks in the 2 ams (donepezil versus non-drug). ZARIT scale = for assessing caregiver burden, scored from 0 to 88
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of Alzheimer's disease according to the IWG-2 criteria.
-
Age ≥ 50 years.
-
Absence of legal protection measures (guardianship, curatorship).
-
MMSE score ≥ 10 at inclusion.
-
abnormal values for Aβ42 in the CSF or Aβ40 / Aβ42 ratio.
-
abnormal values for phosphorylated Tau in CSF
-
Presence of a family carer or a person at home who can ensure compliance with treatment if MMSE score <20.
-
French native speaker.
Exclusion Criteria:
-
Other cause of dementia.
-
Previous use of symptomatic treatment for Alzheimer's disease.
-
Hypersensitivity to donepezil hydrochloride or to any of the excipients listed in the SPC.
-
Cardiological contraindication after possible opinion of a cardiologist, at the initiative of the investigator, in particular bradycardia, sinus disease or other supra-ventricular conduction abnormalities such as sinoatrial or atrioventricular block.
-
Patients at particular risk of ulcer, known ulcer disease or receiving concomitant treatment with non-steroidal anti-inflammatory drugs.
-
Patient at risk of urinary retention.
-
History of epileptic disease.
-
History of neuroleptic malignant syndrome.
-
History of asthma or obstructive bronchopulmonary disease.
-
Severe hepatic impairment.
-
Taking one of the following treatments:
-
CYP3A4 inhibitors, such as ketonazole.
-
2D6 inhibitors, such as quinidine.
-
CYP3A4 inhibitors, such as itraconazole and erythromycin.
-
CYP2D6 inhibitors, such as fluoxetine.
-
Enzyme inducers such as rifampicin, phenytoin, carbamazepine.
-
Participation in another interventional study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cognitive Neurology Center | Paris | France | 75010 |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
- France Alzheimer
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APHP201183